• Contact
  • EPAD Academy
Top Bar Menu
TwitterFacebookYouTube
Search...
EPADEPAD
EPAD
European Prevention of Alzheimer's Dementia Consortium
  • Home
  • About
    • Welcome to EPAD
    • Project Objectives
    • Project Structure
    • EPAD Partners
    • Coordination & Management
    • EPAD Q&A
  • Our research
    • Participation in EPAD
      • Participation in EPAD Cohort
      • EPAD Study Visits
      • Trial Locations
      • Participation FAQs
    • The Participant’s Experience
      • The Research Participant Panel
      • EPAD Stories
    • The EPAD platform
      • The EPAD Platform
      • EPAD Benefits
      • Clinical Candidate Selection
      • EPAD FAQs
      • Research Resources
  • Open Access Data
    • Overview
    • Access
    • Data
    • Samples
    • MRI Images
  • News & Publications
    • Latest News
    • Newsletters
    • Publications
    • Videos
Menu back  

Welcome to the July issue of the EPAD newsletter

2020-07-31News

We are writing to you with the latest news of the EPAD project.

What will the world be like once the COVID-19 pandemic is over? We can all speculate, formulate, hypothesise, hope and fear – we will all have our personal crystal balls – some cloudy, some clearer, some ignored and some stared into constantly – but one thing we can all be sure of is that once this nasty little virus is gone and all we have is the scars there will still be millions upon millions of people with or at risk of Alzheimer’s disease.

The whole world is working under the proposal that: ‘Until we get the vaccine we need to do all we can to make sure we don’t get it.’ This could be paraphrased to apply to Alzheimer’s disease too – we have an ongoing and vital role to do all we can to make sure as few people get it (Alzheimer’s disease) as possible through knowledge generation that drives clinical and public health implementation.

Although the IMI period of EPAD has come to an end for many of us in June and the rest of us in October, the aims, objectives and vision of EPAD persists. National programmes are being developed to follow up all the EPAD participants in a series of linked national and local programmes, the database and biobank is in safe hands with substantial funding from the Alzheimer’s Association and the site network is poised to be substantially extended and we will be offered a wide range of trials through the emerging GAP/EPAD collaboration. It is though a huge pity that we couldn’t initiate the platform trial which – after all – was the primary objective of EPAD. Over the weeks and months ahead though we can formally analyse the reasons for this as platform trials are proving to be of massive value in testing new treatments for COVID-19. Perhaps the Alzheimer’s trials world wasn’t quite ready for us – they will be though one day, hopefully soon…

In amongst all these developments and focus on COVID – we released to the world the V1500.0 dataset on schedule and in September we will release the entire EPAD dataset to the partnership and we will work on global release and open access through our collaboration with the Alzheimer’s Disease Data Interoperability Programme which launches formally very soon.

In essence the incredible and valuable contributions we’ve all made since 2014 – including the contribution of our over 2,000 research participants – has created phenomenal momentum and has generated legacies, assets, opportunities and hope for a huge, inspired and inspirational community. The only real challenge is to make sure we each can remain motivated, committed and believing when the (virtual) world manifests such unreality and such distraction.

One thing that is real and certain though is that once this nasty little virus is gone, hundreds of thousands of people will have died from Alzheimer’s disease who shouldn’t have and millions more will still ‘get it’ in the years ahead. If you were asked – ‘what did you do during the COVID Pandemic?’. ‘I kept working to find a cure for Alzheimer’s disease….’ isn’t too shabby an answer.

We will have a virtual General Assembly meeting in September and with our friends in NEURONET, we will meet as early as we can next year face to face to talk about what we’ve done, what we’re doing and what we still need to do. Until then keep safe and keep the faith.

Craig Ritchie, EPAD Co-coordinator

You can download the newsletter here.

Share this post
FacebookTwitterLinkedInGoogle+
Related posts
The final EPAD dataset is now available to the entire research community
2020-11-30
ALZFORUM
Alzforum conference blog mentions EPAD
2020-11-30
EPAD v1500 dataset
New webpage dedicated to EPAD data and samples on the EPAD website
2020-11-18
ADDI launches new Workbench to foster greater global research innovation and accelerate breakthroughs in Alzheimer’s disease and related dementias
2020-11-17
New paper investigating the prediction of Alzheimer’s disease biomarker status
2020-11-12
The Alzheimer’s Disease Data Initiative supports EPAD
2020-11-06
Latest News
  • The final EPAD dataset is now available to the entire research community
    2020-11-30
  • ALZFORUM
    Alzforum conference blog mentions EPAD
    2020-11-30
  • EPAD v1500 dataset
    New webpage dedicated to EPAD data and samples on the EPAD website
    2020-11-18
  • ADDI launches new Workbench to foster greater global research innovation and accelerate breakthroughs in Alzheimer’s disease and related dementias
    2020-11-17
  • New paper investigating the prediction of Alzheimer’s disease biomarker status
    2020-11-12
View the EPAD Brochure
thumbnail of EPAD brochure
Speak to the EPAD team
thumbnail of speech bubbles
Twitter
Twitter
EPAD
EPAD
@IMI_EPAD

We would like to thank all our followers! A massive thanks also goes to our research participants & members for all their support! Looking back on the years of the @IMI_EPAD project, here's key pictures took at major events. Have a safe & Happy New Year! youtu.be/FeYsOBOhCeo

reply retweet favorite
8:55 am · 2021-01-18
Twitter
EPAD
EPAD
@IMI_EPAD

The videos from #30AEC are online! Check out the @IMI_EPAD presentations on #data sharing by @rodrigobarnes (@aridhia) & Colin Veal (@uniofleicester). Thanks @IMI2_NEURONET and @AlzheimerEurope for giving us the opportunity to present our work. imi-neuronet.org/2020-virtual… twitter.com/IMI2_NEURONET/…

reply retweet favorite
8:43 am · 2021-01-15
Twitter
EPAD
EPAD
@IMI_EPAD

Authors investigated #data from nine studies, including @IMI_EPAD, comprising a total of 60,004 assessed participants. If you want to explore the #Alzheimer's disease data landscape, visit adata.scai.fraunhofer.de @BirkenbihlC @ApitiusHofmann @ddomingof @Simon_Lovestone @TVB_cloud

reply retweet favorite
7:56 am · 2021-01-11
Twitter
EPAD
EPAD
@IMI_EPAD

Numerous studies have collected #Alzheimer's disease cohort #data sets. @BirkenbihlC and colleagues have evaluated the Alzheimer's disease data landscape from a patient‐level data‐centric perspective. @IMI_EPAD @IMI_EMIF @NACCALZ alz-journals.onlinelibrary.wi…

reply retweet favorite
7:48 am · 2021-01-11
Twitter
EPAD
EPAD
@IMI_EPAD

The final @IMI_EPAD dataset is now available to the entire research community | News | @CORDIS_EU | European Commission europa.eu/!dj89jY

reply retweet favorite
12:55 pm · 2021-01-08
Copyright © 2015-19 EPAD | Created by CMAST and Aridhia
  • Acronyms
  • Legal Notice
  • Privacy Policy
Bottom Menu

efpia-logo EU imi logo

This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement nº 115736

This website uses cookies to improve your experience. Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.